InflaRx shares surge 43.09% premarket after positive Phase 2a data for INF904 in HS and CSU show strong efficacy and safety.

InflaRx surged 43.09% in premarket trading following the release of positive Phase 2a clinical trial data for its oral C5aR inhibitor INF904 in treating hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The study demonstrated rapid, meaningful reductions in inflammatory lesions, pain, and urticaria activity scores across both indications, with no serious adverse events reported. Strong safety and efficacy signals, coupled with plans to advance INF904 to Phase 2b trials in HS by 2026 and explore partnerships for CSU development, fueled investor optimism. The company highlighted INF904’s potential as a "pipeline-in-a-product" with a $1 billion addressable market, reinforcing its therapeutic differentiation and growth prospects. These results, announced alongside a webcast and upcoming Q3 2025 financial disclosure, directly drove the sharp premarket rally.